

12 July 2011

Horizon Pharma Inc., a Northbrook, Illinois based drug developer focused on arthritis, pain and inflammatory diseases, has set its IPO terms to 5.5 million common shares being offered at between \$10 and \$12 per share. It would have an initial market cap of \$190-\$230 million, were it to price at the high end of its range. The company plans to trade on the Nasdaq under ticker symbol HZNP, with Stifel Nicolaus Weisel, Cowen & Co. and JMP Securities serving as co-lead underwriters. Horizon Pharma has raised over \$54 million in VC funding from firms like Atlas Venture (17.6% pre-IPO stake), Essex Woodlands Health Ventures (14.1%), Scale Venture Partners (13.6%), NGN Biomed (9.9%), Sutter Hill Ventures (5.9%), FirstMark Capital (7.9%), Global Life Sciences Ventures (7.8%) and TVM (5.7%). www.horizon-pharma.com

More detail on: <http://www.marketwatch.com/story/horizon-pharma-estimates-10-12-a-share-ipo-price-2011-07-11>